Autolus Therapeutics (NASDAQ:AUTL) Stock Rating Reaffirmed by Needham & Company LLC

Autolus Therapeutics (NASDAQ:AUTL – Get Rating)‘s stock had its “buy” rating reiterated by Needham & Company LLC in a note issued to investors on Tuesday, Benzinga reports. They currently have a $7.00 target price on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 243.14% from the stock’s previous close.

Separately, Mizuho decreased their target price on shares of Autolus Therapeutics from $18.00 to $12.00 and set a “buy” rating on the stock in a research report on Wednesday.

Autolus Therapeutics Price Performance

Shares of NASDAQ AUTL opened at $2.04 on Tuesday. The firm has a market capitalization of $353.04 million, a P/E ratio of -1.30 and a beta of 1.59. Autolus Therapeutics has a one year low of $1.60 and a one year high of $4.73. The company’s fifty day moving average is $1.95 and its two-hundred day moving average is $2.40. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.47 and a current ratio of 5.47.

Institutional Investors Weigh In On Autolus Therapeutics

Institutional investors have recently made changes to their positions in the stock. Armistice Capital LLC purchased a new stake in shares of Autolus Therapeutics in the 4th quarter worth about $19,426,000. TFG Asset Management GP Ltd boosted its position in shares of Autolus Therapeutics by 173.1% in the 4th quarter. TFG Asset Management GP Ltd now owns 8,300,000 shares of the company’s stock worth $15,770,000 after buying an additional 5,260,619 shares in the last quarter. Nantahala Capital Management LLC boosted its position in shares of Autolus Therapeutics by 47.2% in the 4th quarter. Nantahala Capital Management LLC now owns 7,782,018 shares of the company’s stock worth $14,786,000 after buying an additional 2,495,930 shares in the last quarter. Pendal Group Ltd boosted its position in shares of Autolus Therapeutics by 26.5% in the 4th quarter. Pendal Group Ltd now owns 1,733,391 shares of the company’s stock worth $3,293,000 after buying an additional 362,634 shares in the last quarter. Finally, Laurion Capital Management LP purchased a new stake in shares of Autolus Therapeutics in the 4th quarter worth about $2,850,000. 70.06% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

(Get Rating)

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells.